Trust Size
$49M
Current Price
$0.00
Peak Market Cap
$400M
Price Journey
What Happened
Clarus Therapeutics was a pharmaceutical company that developed JATENZO, the first FDA-approved oral testosterone replacement therapy for men with hypogonadism. The company went public via SPAC merger with Blue Water Acquisition Corp in 2021. Clarus filed for Chapter 11 bankruptcy in September 2022.
Blue Water Acquisition Corp merged with Clarus Therapeutics in September 2021. Despite having an FDA-approved product (JATENZO), the company struggled with commercial launch, facing competition and slow physician adoption. Just one year after going public, Clarus filed for Chapter 11 in September 2022, making it one of the quickest SPAC-to-bankruptcy cases.
Timeline
2020-11-30
S-1 Registration Filed
2023-03-06
Last SEC Filing
2023-06-20
Filed for bankruptcy
SEC Filing Details
CIK Number
1817944
Total SEC Filings
236
State of Incorporation
DE
Last Filing Date
2023-03-06
Business Location
Greenwich, CT
Trust/Asset Size
$49M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for Clarus Therapeutics Holdings